Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Allbirds Inc (BIRD) vs Cassava Sciences Inc (FLNA) Price & Performance

Allbirds IncTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Allbirds Inc vs Cassava Sciences Inc — how do they compare? Allbirds Inc trades at $3 (market cap $25.89M), while Cassava Sciences Inc trades at $1.09 (market cap $52.66M). The key difference: Cassava Sciences Inc is far larger — about 2× Allbirds Inc's market cap. Which is the better fit depends on your goals.

BIRDFLNA
Market Cap
$25.89M$52.66M
Sector
Consumer CyclicalHealth
52-Week High
$16.99$4.64
52-Week Low
$2.39$1.09
Enterprise Value
$44.76M-$33.92M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Allbirds Inc

BIRD (Smartbird) trades at $3.00, down 4.15% today, amid a complete business pivot from footwear to AI infrastructure. The stock shows a bearish technical trend with all moving averages signaling sell, while oscillators suggest potential oversold conditions. Fundamentally, the company reports declining revenue ($152M in 2025) and persistent losses (-$77M net income), though it maintains a low P/S ratio of 0.17. Recent news highlights the strategic shift, including a rebrand to Smartbird and appointment of a new CEO from Amazon Web Services (Reuters, June 17, 2026).

The outlook is highly speculative, driven by the unproven AI strategy rather than current fundamentals. Investment opportunity lies in potential AI sector growth, but risks include execution challenges, cash burn (-$40M net cash flow in 2025), and intense competition. Analysts are cautious with 79% hold ratings, reflecting uncertainty about the pivot's success. Shareholders face volatility as the company transitions from a tangible product business to technology infrastructure.

Cassava Sciences Inc

FLNA trades at $1.15, down 2.54% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company continues to report losses, with a net income of -$90.97M in 2025 and negative cash flow, though it has beaten EPS estimates for the last three quarters. Recent news highlights ongoing development in its TSC-related epilepsy therapies.

Despite consistent earnings beats, FLNA's negative profitability and cash burn pose significant risks. Analyst sentiment is positive with a 66.7% buy rating, but the stock's outlook depends heavily on clinical success and future funding. Investors should weigh the high-risk, high-reward nature of this biotech play.

Returns comparison

Trailing returns across standard periods

About Allbirds Inc

Allbirds Inc is a global lifestyle brand that innovates with naturally derived materials to make footwear and apparel products. Its primary source of revenue is from sales of shoes and apparel products in its directly owned digital and physical retail channels.

Read more on BIRD

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA